Preliminary results showed potent inhibition of both the Beta and Gamma variants by opaganib at non-cytotoxic doses, the company said.
Opaganib is a unique host-targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of COVID-19.
Comments are closed.